Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/95249
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: CYP2B6*6 allele and age substantially reduce steady-state ketamine clearance in chronic pain patients: impact on adverse effects
Author: Li, Y.
Jackson, K.
Slon, B.
Hardy, J.
Franco, M.
William, L.
Poon, P.
Coller, J.
Hutchinson, M.
Currow, D.
Somogyi, A.
Citation: British Journal of Clinical Pharmacology, 2015; 80(2):276-284
Publisher: Wiley
Issue Date: 2015
ISSN: 0306-5251
1365-2125
Statement of
Responsibility: 
Yibai Li, Kate A. Jackson, Barry Slon, Janet R. Hardy, Michael Franco, Leeroy William, Peter Poon, Janet K. Coller, Mark R. Hutchinson, David C. Currow, and Andrew A. Somogyi
Abstract: AIMS: Ketamine analgesia is limited by low intrinsic efficacy compounded by large interindividual variability in drug responses, possibly due to the heterogeneity in drug concentration. The CYP2B6*6 allele is associated with substantially reduced ketamine metabolism in vitro and, therefore, may affect ketamine clearance. Our aims were to examine the impact of the CYP2B6*6 allele on ketamine plasma clearance and on adverse effects in chronic pain patients. METHODS: CYP2B6 genotypes were identified in 49 chronic pain patients who received 24 h continuous subcutaneous infusions of ketamine. Steady-state plasma concentrations of ketamine (Css,k ) and norketamine (Css,nk ) were determined using HPLC. RESULTS: The median plasma clearance of ketamine after 100 mg 24 h(-1) dose was significantly lower in patients with the CYP2B6*6/*6 (21.6 l h(-1) ) and CYP2B6*1/*6 (40.6 l h(-1) ) genotypes compared with patients with the CYP2B6*1/*1 genotype (68.1 l h(-1) , P < 0.001). The ketamine : norketamine plasma metabolic ratio was significantly higher in patients with the CYP2B6*6/*6 genotype than in those with the CYP2B6*1/*6 and the CYP2B6*1/*1 genotypes (P < 0.001). Patients who experienced adverse effects had lower plasma clearance (45.6 l h(-1) ) than those who did not (52.6 l h(-1) , P = 0.04). The CYP2B6*6 genotype and age, and their combined impact explained 40%, 30% and 60% of the variation in Css,k , respectively. Similar results were observed after higher doses. CONCLUSIONS: The CYP2B6*6 allele is associated with a substantial decrease in steady-state ketamine plasma clearance in chronic pain patients. The decreased clearance and resultant higher plasma concentrations may be associated with a higher incidence of ketamine adverse effects.
Keywords: adverse effects; age factors; cytochrome P-450 CYP2B6; ketamine; metabolic clearance rate; polymorphism
Rights: © 2015 The British Pharmacological Society
RMID: 0030023416
DOI: 10.1111/bcp.12614
Grant ID: http://purl.org/au-research/grants/arc/DP110100297
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.